A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Exclusion Criteria

• •Have severe active lupus nephritis.
• •Have severe active central nervous system (CNS) or peripheral neurologic disease or other severe neurologic involvement requiring treatment within approximately 3 months prior to screening.
• •Have received high dose corticosteroid within approximately 1 month prior to baseline.
• •Have initiated or adjusted treatment with immunosuppressant drugs within approximately 1 month prior to baseline.
• •Have received plasmapheresis within approximately 3 months prior to baseline.
• •Have previously received approved or experimental B cell targeted therapies within the last year.
• •Have received any biologic or non-biologic therapy within approximately 3 months or 5 half-lives (whichever is longer).
• •Have a history of severe reaction to any biologic therapy.
• •Have an active or recent infection within approximately 1 month prior to Week 0.
• •Have had a serious infection within approximately 3 month or serious bone/joint infection within approximately 6 months prior to baseline.
• •Have evidence of or test positive for active hepatitis B or are positive for hepatitis C or human immunodeficiency virus (HIV).
• •Have evidence of active or latent tuberculosis.
• •Have significant hematological abnormalities.